Given Imaging Builds Esophageal Diagnostics Portfolio With Sierra Purchase
This article was originally published in The Gray Sheet
Executive Summary
Given Imaging will bolster its esophageal diagnostics portfolio with the $35 million acquisition of Sierra Scientific Instruments, announced March 22
You may also be interested in...
Capsule Endoscopy: Poised For Growth
The market for capsule endoscopy is one of the fastest growing segments in the multibillion-dollar gastrointestinal endoscopy market. The market opportunity is vast and highly underpenetrated, and an increasing number of competitors, new product innovations, and expanding indications for the technology are positioning capsule endoscopy as a market poised for growth – particularly if the technology is proven and FDA cleared for colon cancer indications.
Given Imaging results
Second quarter sales advanced 17% to $42.1 million, including $5.7 million from recently acquired Sierra Scientific Instruments, the firm reports Aug. 12. Given acquired the esophageal diagnostics marketer in March for $35 mil. (1"The Gray Sheet" March 29, 2010). Global sales of Given's PillCam SB 2 small bowel endoscopy capsules were flat, largely due to fewer procedures in the U.S. gastrointestinal market and economic instability in Europe, according to the company. As a result, the firm is now expecting full-year 2010 sales to be on the lower end of its previous $167 million-$174 million guidance. Given noted that it recently held a pre-IDE meeting with FDA regarding its PillCam COLON 2 clinical trial and that it is still planning to initiate a study in the second half of this year comparing the capsule-based system with standard colonoscopy. A 510(k) filing will follow in the second quarter of 2011, according to the company
Given Imaging results
Second quarter sales advanced 17% to $42.1 million, including $5.7 million from recently acquired Sierra Scientific Instruments, the firm reports Aug. 12. Given acquired the esophageal diagnostics marketer in March for $35 mil. (1"The Gray Sheet" March 29, 2010). Global sales of Given's PillCam SB 2 small bowel endoscopy capsules were flat, largely due to fewer procedures in the U.S. gastrointestinal market and economic instability in Europe, according to the company. As a result, the firm is now expecting full-year 2010 sales to be on the lower end of its previous $167 million-$174 million guidance. Given noted that it recently held a pre-IDE meeting with FDA regarding its PillCam COLON 2 clinical trial and that it is still planning to initiate a study in the second half of this year comparing the capsule-based system with standard colonoscopy. A 510(k) filing will follow in the second quarter of 2011, according to the company